Our vision
Future cancer therapies will predominantly rely on biotherapies, that are mainly administered intravenously.
We broaden access to these cutting-edge treatments by transitioning from intravenous administration to subcutaneous, a faster and more convenient method favored by both patients and hospitals.
Facilitate access to advanced cancer treatments to everyone everywhere with subcutaneous administration
Partners
